Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis presents proof-of-concept cancer study

Novartis presents proof-of-concept cancer study

2nd June 2008

Novartis has presented data which suggests that RAD001 (everolimus) may enhance the efficacy of several commonly-used treatments for breast cancer at the American Society of Clinical Oncology.

Dr Peter Harper, consultant medical oncologist at Guy’s and St Thomas’, explained the research shows potential to improve outcomes for early-stage hormone-sensitive breast cancer patients through the addition of RAD001 to initial treatment with letrozole.

Preclinical studies showed that RAD001 acts on the pathway that controls trastuzumab resistance and also has the potential to help restore response in refractory patients.

“Taken together, the results from all of these trials further underscore RAD001’s promise across various subsets of breast cancers, as well as other tumours, including advanced kidney cancer,” he added.

The firm noted that it intends to carry out further exploration of RAD001’s potential with regard to breast cancer treatment by carrying out a new trial in the early part of 2009.

Novartis recently announced the approval of Extavia in the European Union as a treatment for multiple sclerosis.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.